8-K: Dyadic International Reports Q1 2025 Financial Results, Highlights Commercialization Progress

Dyadic International announced its Q1 2025 financial results, showcasing progress in commercializing its protein production platforms and expanding its life science and industrial portfolio.

Summary

• Dyadic International reported its financial results for the first quarter of 2025.
• The company is focused on commercializing its Dapibus and C1 microbial protein production platforms.
• Dyadic is targeting growth in life sciences, bioactives, ingredients, and industrial markets.
• Revenue for Q1 2025 increased to approximately $394,000, compared to $335,000 for the same period last year.
• The increase in revenue was driven by a $210,000 increase in grant revenue from the Gates Foundation and CEPI grants.
• Cash, cash equivalents, and investment-grade securities totaled $7.3 million as of March 31, 2025, compared to $9.3 million as of December 31, 2024.
• The net loss for the quarter was $2,028,000, compared to $2,010,000 for the same period last year.
• The company is progressing towards commercial launch of Human Serum Albumin in partnership with Proliant Health and Biologicals in Q3 2025.
• Dyadic initiated a $3 million project with the Gates Foundation to develop low-cost monoclonal antibodies for malaria and RSV.
• Dyadic's C1 platform is being advanced through a $4.5 million CEPI grant through FBS to accelerate recombinant protein vaccine development and manufacturing.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, there was also an increase in revenue and a decrease in operating loss. The company is also making progress in commercializing its technology and has secured funding from reputable organizations.

Positives

• Revenue increased to $394,000 in Q1 2025 from $335,000 in Q1 2024, driven by grant revenue.
• Loss from operations decreased to $2,002,000 in Q1 2025 from $2,126,000 in Q1 2024.
• General and administrative expenses decreased by 10.8% to $1,596,000.
• Dyadic is progressing towards commercial launch of Human Serum Albumin in partnership with Proliant Health and Biologicals in Q3 2025.
• The company is developing and validating prototypes for four additional enzymes, including RNase Inhibitors and T7 RNA Polymerase, to support the growing demand for DNA/RNA manipulation tools.

Negatives

• Cash, cash equivalents, and investment-grade securities decreased to $7.3 million as of March 31, 2025, from $9.3 million as of December 31, 2024.
• Net loss increased to $2,028,000 for Q1 2025 compared to $2,010,000 for the same period a year ago.
• Other income decreased due to increased interest expenses and the absence of a gain on the sale of Alphazyme that occurred in 2024.
• Cost of research and development revenue and cost of grant revenue increased to approximately $298,000 compared to $144,000 for the same period a year ago.

Risks

• The company has a history of net losses.
• Market and regulatory acceptance of Dyadic's microbial protein production platforms and other technologies is uncertain.
• Failure to commercialize the microbial protein production platforms or other technologies poses a risk.
• Competition from alternative technologies could impact Dyadic's success.
• The results of nonclinical studies and clinical trials are uncertain.
• Dyadic has capital needs that must be met.
• Changes in global economic and financial conditions could impact the company.
• Reliance on information technology poses a risk.
• Dependence on third parties could impact Dyadic's operations.
• Government regulations and environmental, social, and governance issues could impact the company.
• Intellectual property risks exist.

Future Outlook

Dyadic remains committed to expanding the reach of its C1 and Dapibus platforms by developing functional recombinant solutions for non-therapeutic applications that can be both commercialized and licensed.

Management Comments

• Mark Emalfarb, CEO of Dyadic, stated that the company's primary focus is on developing and commercializing scalable products with recurring revenue potential.
• Mr. Emalfarb believes Dyadic is making meaningful progress in returning to its core strength, utilizing its proprietary microbial protein production platforms to drive revenue growth in high-value markets.
• Mr. Emalfarb stated that Dyadic is well-positioned to advance innovation, broaden global access to affordable biologics, proteins and enzymes, and lower production costs, ultimately providing a stable foundation for long-term shareholder value.

Industry Context

Dyadic's focus on recombinant protein production platforms aligns with the growing demand for biologics, vaccines, and enzymes in the life science, nutrition, and industrial sectors. The company's collaborations with CEPI and the Gates Foundation highlight its potential to contribute to global health initiatives. Participation in the European Vaccines Hub for Pandemic Readiness (EVH) project positions Dyadic to play a role in future vaccine development and manufacturing efforts.

Comparison to Industry Standards

• Dyadic's C1 platform aims to offer a cost-effective alternative to traditional protein production systems like CHO cells or E. coli, which are commonly used by companies such as Genentech (Roche), Amgen, and Biogen.
• The company's focus on non-animal cell culture media aligns with the industry trend towards reducing reliance on animal-derived components, similar to efforts by companies like Thermo Fisher Scientific and Merck KGaA.
• Dyadic's work on vaccines and antibodies is comparable to companies like Moderna and Pfizer, although Dyadic is primarily focused on the production platform rather than the development of specific vaccine candidates.
• The collaboration with Fermbox Bio to produce enzyme cocktails for cellulosic sugar production is similar to the work of companies like Novozymes and DSM in the industrial biotechnology sector.

Stakeholder Impact

• Shareholders: The company is focused on driving long-term shareholder value through commercialization and licensing of its platforms.
• Employees: The company's strategic pivot and focus on commercialization may impact employee roles and responsibilities.
• Customers: The company aims to provide affordable biologics, proteins, and enzymes to its customers.
• Partners: The company is expanding its network of partners and collaborators to develop and commercialize its technologies.
• Global Health: The company's collaborations with CEPI and the Gates Foundation aim to broaden global access to affordable biologics.

Next Steps

• Progress toward commercial launch of Human Serum Albumin in Q3 2025.
• Achieve a third milestone payment in Q2 2025 related to productivity improvements and future revenue sharing payments for commercial sales of Human Serum Albumin.
• Continue protein characterization testing to support the use of recombinant alpha-lactalbumin.
• Continue optimization and characterization efforts for human lactoferrin, with sampling efforts expected to begin in late 2025.
• Continue scale up and commercialization efforts for a recombinant dairy enzyme, with an anticipated launch in late 2025.
• Validate the production process for DNase1 (RNase-Free) and the initial manufacture of research-grade material for purchase.
• Continue development and optimization of four additional enzymes, including RNase Inhibitors and T7 RNA Polymerase, with results expected by the end of 2025.
• Advance Dyadic's C1 platform through a $4.5 million CEPI grant through FBS to accelerate recombinant protein vaccine development and manufacturing.
• Continue the $3 million project with the Gates Foundation focused on developing low-cost monoclonal antibodies for malaria and respiratory syncytial virus (RSV) using its C1 expression platform.

Key Dates

Keywords

Dyadic International, C1 platform, Dapibus, Recombinant proteins, Enzymes, Biotechnology, Vaccines, Antibodies, Financial results, Commercialization